Literature DB >> 25791455

N-Sulfonyl-β-lactam hapten as an effective labeling reagent for aldolase mAb.

Tsubasa Inokuma1, Roberta P Fuller2, Carlos F Barbas2.   

Abstract

Utilization of chemically programmed antibodies (cpAbs) is regarded to be one of the most efficient methods for the development of therapeutic systems. cpAbs can extend the half-life of programming reagents, activate immune systems via the Fc region of antibodies and achieve universal vaccination by attaching varieties of small, programmed molecules. In the current study, we aimed to develop a novel labeling reagent for the preparation of cpAbs and found that N-sulfonyl-β-lactams (NSBLs) were optimal. NSBL can be synthesized from readily available 4-(bromomethyl)benzenesulfonyl chloride via few simple manipulations and can label the aldolase monoclonal antibody (mAb) 84G3, which could not be labeled effectively by the conventional labeling reagent, N-acyl-β-lactam (NABL). We also demonstrated that the conjugate, which consists of mAb 84G3 and an NSBL bearing a biotin moiety, maintained strong binding activity to streptavidin. In addition, the stability assay of NSBL revealed that NSBLs can tolerate aqueous media without significant decomposition over 24h.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Aldolase antibody; Bioconjugation; Chemically programmed antibody; N-Sulfonyl-β-lactam

Mesh:

Substances:

Year:  2015        PMID: 25791455      PMCID: PMC4527526          DOI: 10.1016/j.bmcl.2015.03.011

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  31 in total

Review 1.  Improving the efficacy of antibody-based cancer therapies.

Authors:  P Carter
Journal:  Nat Rev Cancer       Date:  2001-11       Impact factor: 60.716

2.  Chemically programmed monoclonal antibodies for cancer therapy: adaptor immunotherapy based on a covalent antibody catalyst.

Authors:  Christoph Rader; Subhash C Sinha; Mikhail Popkov; Richard A Lerner; Carlos F Barbas
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-17       Impact factor: 11.205

3.  Synthesis and characterization of hapten-protein conjugates for antibody production against small molecules.

Authors:  K V Singh; Jasdeep Kaur; Grish C Varshney; Manoj Raje; C Raman Suri
Journal:  Bioconjug Chem       Date:  2004 Jan-Feb       Impact factor: 4.774

4.  Antibody conjugate therapeutics: challenges and potential.

Authors:  Beverly A Teicher; Ravi V J Chari
Journal:  Clin Cancer Res       Date:  2011-10-15       Impact factor: 12.531

5.  Chemically programmed antibodies: endothelin receptor targeting CovX-Bodies.

Authors:  Venkata R Doppalapudi; Nancy Tryder; Lingna Li; Teresa Aja; David Griffith; Francesca-Fang Liao; Giovanni Roxas; Mysore P Ramprasad; Curt Bradshaw; Carlos F Barbas
Journal:  Bioorg Med Chem Lett       Date:  2006-10-07       Impact factor: 2.823

6.  Preparation of integrin alpha(v)beta3-targeting Ab 38C2 constructs.

Authors:  Subhash C Sinha; Sanjib Das; Lian-Sheng Li; Richard A Lerner; Carlos F Barbas
Journal:  Nat Protoc       Date:  2007       Impact factor: 13.491

7.  Preparation and characterization of monoclonal antibody conjugates of the calicheamicins: a novel and potent family of antitumor antibiotics.

Authors:  L M Hinman; P R Hamann; R Wallace; A T Menendez; F E Durr; J Upeslacis
Journal:  Cancer Res       Date:  1993-07-15       Impact factor: 12.701

8.  An efficient chemical approach to bispecific antibodies and antibodies of high valency.

Authors:  Julia I Gavrilyuk; Ulrich Wuellner; Syed Salahuddin; Rajib K Goswami; Subhash C Sinha; Carlos F Barbas
Journal:  Bioorg Med Chem Lett       Date:  2009-05-18       Impact factor: 2.823

Review 9.  Antibody-drug conjugates for cancer therapy.

Authors:  Paul J Carter; Peter D Senter
Journal:  Cancer J       Date:  2008 May-Jun       Impact factor: 3.360

10.  Chemically Programmed Antibodies AS HIV-1 Attachment Inhibitors.

Authors:  Shinichi Sato; Tsubasa Inokuma; Nobumasa Otsubo; Dennis R Burton; Carlos F Barbas
Journal:  ACS Med Chem Lett       Date:  2013-05-09       Impact factor: 4.345

View more
  1 in total

1.  Ligand-Enabled β-C(sp3 )-H Lactamization of Tosyl-Protected Aliphatic Amides Using a Practical Oxidant.

Authors:  Zhe Zhuang; Shuang Liu; Jin-Tang Cheng; Kap-Sun Yeung; Jennifer X Qiao; Nicholas A Meanwell; Jin-Quan Yu
Journal:  Angew Chem Int Ed Engl       Date:  2022-07-14       Impact factor: 16.823

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.